Massachusetts biotech: growth-stage money is back, seed money and NIH awards are not

Divide the federal money by the awards and the shape of the problem gets clearer. Massachusetts institutions took in $3.413 billion of NIH funding in 2025 ^[7] across 5,423 grants ^[8], an average of roughly $629,000 per award against about $598,000 the year before, with 359 fewer awards in total ^[19]. The cluster lost grants and gained about 5% on the mean size of the ones it kept. That is the arithmetic under Ben Bradford's objection: MassBio's head of external affairs told GEN that a one percent funding dip is "not the end of the world," but that the drop in award count is "just fewer shots on goal" in an industry with a high failure rate ^[11]. Concentration is the mechanism. The same money reaches fewer principal investigators, and each surviving grant carries more of the state's early science.

The seed figures are stranger. Twenty-one deals sharing $4.65 million works out to about $221,000 apiece, against roughly $510,000 a year earlier ^[6][17]: the average check fell about 57% while the deal count rose 40% ^[18]. Taken at face value that aggregate is small for a cluster of this size, which suggests the report is measuring a narrow slice of pre-Series A activity rather than everything a founder would call seed. The direction holds either way. More companies are getting funded, each with less runway, and they will return to market needing a Series A in a market MassBio describes as healthy chiefly at the growth stage ^[1].

The job losses are R&D-shaped. Of the 3,605 net positions gone in 2025 ^[9], 2,563 were in research and development ^[10], about 71% of the decline ^[20], leaving non-R&D headcount down roughly 1,042 jobs, or 2% ^[21]. Bradford attributes the contraction to pipeline reprioritization at large companies plus shrinkage among small ones, with the sharpest R&D drop between the second and third quarters of 2025 and a partial recovery by the fourth ^[4]. Among the 20 largest employers in the report, eight cut headcount and two were flat, so half the top of the market added nobody ^[14][22].

Takeda, the state's largest biopharma employer, is reported down 181 jobs to 5,628 ^[15]. That net figure sits below the 247 positions the company eliminated in Massachusetts in March, a gap of 66 ^[16][23], so either the measurement windows differ or hiring partly offset the cuts. Neither reading includes the 4,500 worldwide reductions Takeda announced in May ^[16], which land in next year's snapshot.

None of this dents the cluster's ranking, which GEN still puts first in the country ^[2]. What it dents is the number of independent bets Massachusetts can run at once, at the same moment its industry group is weighing the competitive pressure from China's biopharma ecosystem ^[5] and Bradford is conceding that the big picture looks good only until you drill into it ^[12].